- Home
- EML vs INBX Comparison
EML vs INBX Comparison
Compare EML & INBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EML
- INBX
- Stock Information
- Founded
- EML 1858
- INBX 2010
- Country
- EML United States
- INBX United States
- Employees
- EML N/A
- INBX N/A
- Industry
- EML Industrial Machinery/Components
- INBX Biotechnology: Pharmaceutical Preparations
- Sector
- EML Consumer Discretionary
- INBX Health Care
- Exchange
- EML Nasdaq
- INBX Nasdaq
- Market Cap
- EML 191.3M
- INBX 218.9M
- IPO Year
- EML N/A
- INBX 2020
- Fundamental
- Price
- EML $26.66
- INBX $12.74
- Analyst Decision
- EML
- INBX Hold
- Analyst Count
- EML 0
- INBX 1
- Target Price
- EML N/A
- INBX N/A
- AVG Volume (30 Days)
- EML 11.4K
- INBX 74.4K
- Earning Date
- EML 11-01-2024
- INBX 11-14-2024
- Dividend Yield
- EML 1.66%
- INBX N/A
- EPS Growth
- EML N/A
- INBX N/A
- EPS
- EML N/A
- INBX 119.38
- Revenue
- EML $284,461,286.00
- INBX $1,568,000.00
- Revenue This Year
- EML N/A
- INBX N/A
- Revenue Next Year
- EML N/A
- INBX N/A
- P/E Ratio
- EML $13.23
- INBX $0.11
- Revenue Growth
- EML 7.70
- INBX 19.24
- 52 Week Low
- EML $22.63
- INBX $10.80
- 52 Week High
- EML $35.78
- INBX $18.95
- Technical
- Relative Strength Index (RSI)
- EML 43.93
- INBX 32.23
- Support Level
- EML $25.31
- INBX $13.57
- Resistance Level
- EML $26.90
- INBX $16.83
- Average True Range (ATR)
- EML 0.69
- INBX 0.94
- MACD
- EML 0.00
- INBX -0.21
- Stochastic Oscillator
- EML 54.66
- INBX 1.68
About EML Eastern Company (The)
The Eastern Co manages industrial businesses that design, manufacture, and sell engineered solutions to industrial markets. The company manages the financial, operational, and strategic performance of its businesses to increase cash generation, operating earnings, and long-term shareholder value. It operates in the United States and Other Countries and generates the majority of its revenue from the United States.
About INBX Inhibrx Inc.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.